ACUMEN PHARMACEUTICALS
Acumen is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target amyloid-beta oligomers, (AβOs), which Acumen believes to be a key underlying cause of Alzheimer’s disease, or AD. Acumen is currently focused on advancing a targeted immunotherapy drug candidate, ACU193, to establish proof of mechanism in early AD patients. Acumen initiated its Phase 1 clinical trial of ACU193 in the second quarter of 2021 with the objective to evaluate its safety and ... tolerability and explore its pharmacokinetics and target engagement. This trial is currently enrolling patients with mild cognitive impairment and mild dementia due to AD. ACU193 Phase 1 data intended to evaluate safety and tolerability and demonstrate clinical proof of mechanism are expected by year end 2022.
ACUMEN PHARMACEUTICALS
Industry:
Biotechnology Health Diagnostics Therapeutics
Founded:
1996-01-01
Address:
Carmel, Indiana, United States
Country:
United States
Website Url:
http://www.acumenpharm.com
Total Employee:
11+
Status:
Active
Contact:
+1 6508757772
Email Addresses:
[email protected]
Total Funding:
295.1 M USD
Technology used in webpage:
IPv6 COVID-19 Gravity Forms Akamai Hosted
Similar Organizations
Aclaris Therapeutics
Aclaris Therapeutics is a specialty pharmaceutical company engaged in developing dermatologic therapies.
Excision BioTherapeutics
Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients.
Locanabio
Locana develops RNA-targeting gene therapies for patients with severe neurodegenerative, neuromuscular, and retinal diseases.
Proclara Biosciences
Proclara is pioneering a new approach to treating neurodegenerative diseases.
Nurix Therapeutics
Nurix Therapeutics is a biopharmaceutical company that focuses on the development and discovery of small molecule drugs.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
K2 HealthVentures
K2 HealthVentures investment in Post-IPO Debt - Acumen Pharmaceuticals
PBM Capital Group
PBM Capital Group investment in Series B - Acumen Pharmaceuticals
RA Capital Management
RA Capital Management investment in Series B - Acumen Pharmaceuticals
Rock Springs Capital
Rock Springs Capital investment in Series B - Acumen Pharmaceuticals
BlackRock
BlackRock investment in Series B - Acumen Pharmaceuticals
Sands Capital Ventures
Sands Capital Ventures investment in Series B - Acumen Pharmaceuticals
PBM Capital Group
PBM Capital Group investment in Series A - Acumen Pharmaceuticals
Sands Capital Ventures
Sands Capital Ventures investment in Series A - Acumen Pharmaceuticals
National Institute on Aging
National Institute on Aging investment in Grant - Acumen Pharmaceuticals
NeuroVentures
NeuroVentures investment in Venture Round - Acumen Pharmaceuticals
Key Employee Changes
| Date | New article |
|---|---|
| 2024-02-01 | Acumen Pharmaceuticals Appoints Dr. James Doherty as President and Chief Development Officer |
Official Site Inspections
http://www.acumenpharm.com Semrush global rank: 3.3 M Semrush visits lastest month: 4.26 K
Unable to get host informations!!!
More informations about "Acumen Pharmaceuticals"
About Us | Acumen Pharmaceuticals
Acumen doubles the size of the organization to 34 employees and advances the INTERCEPT-AD trial, continues enrollment with projected top-line results in 2023. 2023. Acumen reports positive results from Phase 1 INTERCEPT-AD Trial …See details»
Our Team | Acumen Pharmaceuticals
Passionate. Dedicated. Life science professionals and Alzheimer’s experts. This is the Acumen team. Industry and functional experts. Our foundation is built on collective learnings—and we aspire to deliver treatments that can substantially …See details»
Acumen Pharmaceuticals, Inc. | LinkedIn
Acumen Pharmaceuticals, Inc. Biotechnology Research Greater Boston, MA 5,043 followers Forging a new path towards a safe and effective treatment for Alzheimer’s disease.See details»
Acumen Pharmaceuticals - Crunchbase Company …
Contact Email [email protected] Phone Number +1 6508757772 Acumen is a clinical-stage biopharmaceutical company developing a novel disease …See details»
Acumen Pharmaceuticals Company Profile | Management and
Www.acumenpharm.com Acumen Pharmaceuticals Profile and History Acumen is a clinical-stage biopharmaceutical company developing targeted therapies for the safe and effective treatment …See details»
Overview, News & Similar companies - ZoomInfo.com
Jul 11, 2024 Acumen Pharmaceuticals contact info: Phone number: (434) 297-1000 Website: www.acumenpharm.com What does Acumen Pharmaceuticals do? Acumen is a clinical-stage …See details»
Acumen Pharmaceuticals, Inc. (ABOS) Company Profile …
See the company profile for Acumen Pharmaceuticals, Inc. (ABOS) including business summary, industry/sector information, number of employees, business summary, corporate governance, key executives ...See details»
Governance Overview - Acumen Pharmaceuticals, Inc
The Investor Relations website contains information about Acumen Pharmaceuticals, Inc's business for stockholders, potential investors, and financial analysts.See details»
Acumen Pharma CEO and Key Executive Team | Craft.co
Acumen Pharma's President & Chief Executive Officer is Daniel O'Connell. Other executives include Eric Siemers, Chief Medical Officer; Russell Barton, Chief Operating Officer and 2 …See details»
News Release Details - investors.acumenpharm.com
Nov 12, 2024 For more information, visit www.acumenpharm.com. Forward-Looking Statements This press release contains forward-looking statements within the meaning of The Private …See details»
Working At Acumen Pharma: Company Overview and Culture
Mar 14, 2024 acumenpharm.com. Organization Type. Private. Acumen Pharmaceuticals is a discovery stage biotechnology company focused on discovering and developing in partnership …See details»
Acumen Pharmaceuticals, Inc. Information - RocketReach
Acumenpharm.com; View Similar People. Related Companies One Heart Healing Center. 8 $10m K2 Dental Arts. 9 $6m Charlottesville Dental Health Partners. 4 $4m Diffusion …See details»
Acumen Pharmaceuticals - PitchBook
Acumen Pharmaceuticals General Information Description. Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to …See details»
News Release Details - investors.acumenpharm.com
Nov 26, 2024 The live webcast may be accessed under the Investors tab on www.acumenpharm.com and will be archived for 90 days. About Acumen Pharmaceuticals, …See details»
Acumen Pharmaceuticals, Inc. | Newton MA - Facebook
Acumen Pharmaceuticals, Inc., Newton, Massachusetts. 2,355 likes · 2 talking about this. Forging a new path towards a safe and effective treatment for Alzheimer’s disease.See details»
Acumen Pharmaceuticals to Participate in the Stifel - GlobeNewswire
Nov 11, 2024 The live webcast may be accessed under the Investors tab on www.acumenpharm.com and will be archived for 90 days. About Acumen Pharmaceuticals, Inc.See details»
For Patients | Acumen Pharmaceuticals
Clinical Trials. Before new medications can be approved for public use, they must be tested in clinical research studies. When you participate in a clinical study, you provide valuable …See details»
about_ | Acumen Pharmaceuticals
We use two broad categories of cookies: (1) first party cookies, served directly by us to your computer or mobile device, which we use to recognize your computer or mobile device when it …See details»
Acumen Pharmaceuticals, Inc. and Halozyme Enter Global
Nov 6, 2023 Expect to initiate Phase 1 development in mid-2024 to compare pharmacokinetics of subcutaneous form to intravenous form of ACU193. November 06, 2023 07:30 ET | Source: …See details»